Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$16.49 USD
-0.24 (-1.43%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $16.38 -0.11 (-0.67%) 6:54 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RCUS 16.49 -0.24(-1.43%)
Will RCUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
Other News for RCUS
Hold Rating on Arcus Biosciences Amid TIGIT Inhibitor Uncertainties
Barclays Gives a Buy Rating to Arcus Biosciences (RCUS)
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
Arcus up 4% following Merck Welireg kidney cancer data
Arcus Biosciences Announces New Employment Inducement Grants